24 results about "Drug formulations" patented technology

Described herein are systems and methods that combine at least three different detection modalities to characterize the stability of drug formulations, and sample plates for use with the systems and methods. The systems may include a clamp configured to apply a force to the sample plates that trap and pressurize air above an inlet and / or outlet of sample holders included in the sample plates. Measurements of various parameters of the samples may be obtained in tandem or simultaneously with a single instrument, which reduces sample volume requirements.

An arylboron compound, its preparation method, applications, and pharmaceutical compositions are disclosed for tumor imaging. The compound of formula (I) exhibits high fluorescence quantum efficiency through intramolecular charge transfer. The compound of formula (I) synthesized in this invention can be linked to different antibodies via Q3 at certain concentrations, allowing for precise targeting of corresponding tumors based on the antibody. This type of boron drug formulation can be used in boron neutron capture therapy to kill tumor cells. It exhibits better killing effects; the compound of formula (I) targets tumor cells through antigen-antibody interaction. After the boron-10-containing drug accumulates at the tumor site, neutron radiation triggers a nuclear reaction releasing alpha particles and... 7 Lithium particles kill cells; the range of these two particles is approximately 10 μm. High-energy-density heavy ions disrupt the DNA double helix structure in tumor cells, causing irreparable cell death. Simultaneously, the 10 μm distance avoids damage to normal cells and tissues.

An analyte sensor, a preparation method and an application thereof are provided. The analyte sensor includes a sensing probe, an auxiliary needle and a drug formulation. The auxiliary needle includes a needle tip, a side wall and a bottom wall. The needle tip is connected to the bottom wall. An accommodating groove is defined by the side wall and the bottom wall connected to each other. The accommodating groove is configured to accommodate the sensing probe. The drug formulation is disposed on the auxiliary needle and / or on the sensing probe.

Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided.

This invention discloses a biomimetic system simulating lung tissue, its manufacturing method, and a method for controlling microfluidics using this biomimetic system. The biomimetic system comprises lung epithelial cells, lung fibroblasts, and human umbilical vein endothelial cells isolated from human lungs, and is perfused with microfluidics. Gas and a fluid including culture medium can be perfused into the internal chambers of the system, simulating similar respiratory movements. Even after more than a week following perfusion, the three types of cells within the system can survive. Furthermore, pH and pO2 within the chambers can be monitored using pH and gas partial pressure sensors within the system, allowing the three types of cells to be exposed to the external environment or drugs under conditions similar to those of a living lung. This enables research in a wide range of fields, including modeling lung diseases caused by harmful substances and testing the efficacy of therapeutic drugs. It is also applicable to in vitro disease modeling and customized drug formulation.

This invention relates to the field of fluorescent carbon nanomaterials, specifically to highly efficient water-soluble carbon dots for loading local anesthetic drugs, their preparation method, and applications. Using water-soluble amino acids and carboxylic acid compounds that readily aggregate and carbonize to form six-membered rings as precursors, the precursors are sonicated to dissolve them in an organic solvent to form a homogeneous solution. This solution is then transferred to a reaction vessel and subjected to a solvothermal reaction at 180-240°C for 4-10 hours. The reaction vessel is then allowed to cool naturally to room temperature, directly obtaining a carbon dot solution. The obtained carbon dot solution is filtered, eluted, and dried to obtain a solid carbon dot powder. The functionalized carbon dots prepared by this invention possess both good water solubility and high efficiency in loading local anesthetic drugs, showing broad application prospects in the field of sustained-release analgesia of local anesthetic drug formulations.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

Provided are a crystal form of fruquintinib and a preparation method therefor. Specifically, a crystal form AZT-III of a compound represented by formula (I) is provided. The crystal form AZT-III of fruquintinib has a significant stability advantage, and avoids spontaneous polymorph transformation in high-temperature and high-humidity environments; the crystal form AZT-III has almost no hygroscopicity and has good fluidity, which are beneficial to the subsequent development of drug formulations; in addition, the preparation process of the crystal form AZT-III is simple, involves a convenient and economical solvent system, and is suitable for industrial scale-up production, thus providing a better choice for the development of fruquintinib-containing drugs.

This invention relates to the field of photodynamic therapy for keloids, and discloses a mitochondrial-targeted photodynamic keloid therapeutic agent based on platinum complexes and its application. The agent is prepared by coordinating the organic ligand TBQQ with an activated cisplatin derivative in a 1:1 molar ratio, followed by column chromatography purification to produce a high-purity TBQQPt powder with an active ingredient purity ≥98%. The prepared TBQQPt powder is then administered through a standardized drug formulation, intratumoral administration, and photo-activation process, combined with a multi-dimensional efficacy monitoring and safety evaluation system. Leveraging the D-A type planar square coordination structure of TBQQPt, which endows it with type I / II mixed photodynamic reaction characteristics, mitochondrial targeting, and photocatalytic oxidation of NADH, it synergistically exerts a dual effect of energy deprivation and genome disruption, effectively inducing mitochondrial dysfunction and apoptosis of keloid fibroblasts, and inhibiting their proliferation.

This invention provides a crystalline CSF-1R inhibitor acid salt, its preparation method, and its applications. The CSF-1R inhibitor is a compound having the structure of formula (I), namely 3,3-dimethyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide. The crystalline acid salt compound significantly improves the physicochemical properties of the free form of formula (I), such as solubility, hygroscopicity, and chemical stability, meeting the requirements of industrial production and satisfying the needs of clinical drug formulation development. The crystalline acid salt compound can be widely used in the preparation of drugs for treating cancer, tumors, autoimmune diseases, metabolic diseases, or metastatic diseases.

Various embodiments of the present disclosure provide methods and apparatus for reducing pain associated with injection of certain drug formulations. An apparatus as described herein comprises a first chamber or section containing a pharmaceutical formulation comprising menotropin or a variant thereof, a second chamber or section comprising a diluent, and a combining mechanism configured to puncture one or more of the first chamber or the section chamber to combine the pharmaceutical formulation and the diluent prior to injection. A method as described herein comprises actuating a combining mechanism which combines a pharmaceutical formulation comprising menotropin or a variant thereof and a diluent, and actuating an administering means which administers the pharmaceutical formulation and the diluent to a patient.

Methods for intranasal delivery of GLP-1 (glucagon-like peptide-1) drugs, such as tirzepatide (TZP), using drug formulations encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with chitosan (CS) and / or chitosan grafted with polyethylenimine (CS-PEI) under optimized conditions for surface charge alteration and particle size control. The resulting formulations successfully provided dose-dependent body fat reduction in mice, showing significant therapeutic effects.

This invention belongs to the field of biomedical technology and provides a mussel adhesive protein and azelastine hydrochloride nasal thermosensitive gel, its preparation and application. The mussel adhesive protein and azelastine hydrochloride nasal thermosensitive gel includes an active ingredient and pharmaceutically acceptable excipients. The active ingredient is recombinant mussel adhesive protein mefp-5 subtype and azelastine hydrochloride. The excipients include a thermosensitive polymer, which is mixed with the active ingredient to form a thermosensitive gel system. This invention solves the technical problem that existing single-drug formulations cannot simultaneously provide rapid symptom relief and long-term mucosal barrier repair for allergic rhinitis by combining recombinant mussel adhesive protein mefp-5 subtype with mucosal repair function with azelastine hydrochloride, which has rapid anti-allergic effects. Pharmacodynamic studies have confirmed that the two active ingredients exhibit a significant synergistic effect (CDI < 0.7) in improving allergy symptoms, inhibiting inflammatory responses, and repairing the mucosal barrier.

The present invention relates to a pharmaceutical composition comprising hyaluronic acid or a salt thereof, the molecular weight of which is greater than 2 MDa, and at least 8 amino acids which are essential for humans, selected from the group consisting of lysine, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, threonine and histidine. The invention also relates to uses of the pharmaceutical composition for improving wound healing, for hydrating healthy tissue and / or a wound, for improving cell viability, for improving cartilage and / or joint regeneration, or for improving tissue or cell grafting and / or transplantation.

This invention discloses a verbascoside isoflavone composition and its application in anti-hepatocellular carcinoma and immune remodeling, relating to the field of natural drug formulation technology. The active ingredient of this composition consists of verbascoside, rhodioloside, and taraxasterol in a mass ratio of 42:37:11. The pharmaceutical excipients of the composition consist of pharmaceutical trehalose, sulfobutyl-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin in a mass ratio of 0.4:0.5:0.9. The mass ratio of the pharmaceutical excipients to the total active ingredient is 1.8:1. This invention constructs a multi-target active system through the precise compounding of three plant monomers, synergistically inhibiting hepatocellular carcinoma and regulating immunity. Low-temperature purification using a composite enzymatic hydrolysis coupled with macroporous resin ensures strict purity control and improves bioavailability. A multi-cyclodextrin complex with trehalose is used to construct an inclusion carrier, which improves water solubility and stability through stepwise encapsulation. Gradient freeze-drying is then used to form a powder for injection, which is rapidly and clearly reconstituted. The simplified excipient ratio reduces the metabolic burden on the liver and is suitable for the injection administration needs of hepatocellular carcinoma patients.

This utility model relates to the field of pharmaceutical preparation technology and discloses an antimicrobial peptide chromatography column distributor, including a drug formulation reaction component. The drug formulation reaction component includes a chromatography column body, a positioning mechanism on the outside of the chromatography column body, a drug dispersion component for uniformly dispersing the antimicrobial peptide agent at the upper end of the chromatography column body, a placement component at the upper end of the chromatography column body, a support component on one side of the drug formulation reaction component, and a ball valve at the lower end of the drug formulation reaction component. The drug dispersion component uses a micro-pump to push the agent to be uniformly distributed in the chromatography column body, avoiding the generation of unevenness. The positioning mechanism and the support component provide stable support, ensuring that the positional accuracy of each component is not disturbed during operation. The ball valve precisely adjusts the agent outflow rate, ensuring the stability of the agent flow rate and avoiding the negative impact of uneven flow rate on the drug effect.

An analgesic moxibustion stick for treating primary dysmenorrhea caused by cold stagnation and blood stasis effectively solves the problem of preparing medication for this type of dysmenorrhea. The analgesic moxibustion stick consists of a medicinal core and a paper roll. The medicinal core is made by mixing a compound powder of traditional Chinese medicine with moxa wool and stirring thoroughly. The compound powder of traditional Chinese medicine is composed of warming and dispersing cold herbs, blood-activating and stasis-removing herbs, meridian-guiding herbs, and transdermal adjuvants. The warming and dispersing cold herbs are made by mixing cinnamon, dried ginger, and evodia rutaecarpa powder; the blood-activating and stasis-removing herbs are made by mixing angelica sinensis, chuanxiong rhizome, red peony root, and peach kernel powder; the meridian-guiding herbs are made by mixing asarum and cyperus rhizome powder; and the transdermal adjuvant is borneol. The paper roll is made of double-layered mulberry bark paper rolled using conventional methods. The medicinal core is then placed inside the paper roll. This invention uses abundant raw materials, has a simple preparation method, is easy to produce, and has a scientifically sound drug formulation. It has the effects of warming yang and dispersing cold, activating blood and unblocking collaterals, and has good efficacy, making it valuable for practical application.

This invention belongs to the technical field of novel excipients and dosage forms for pharmaceutical preparations, and relates to a method for preparing reduction-responsive, biodegradable, ionizable lipids, the construction of siRNA lipid nanoparticles, and their application in nucleic acid drug delivery. The preparation method of this invention is simple and easy to implement. By introducing reduction-sensitive disulfide bonds into the ionizable lipid structure, the prepared lipid nanoparticles degrade under the action of high glutathione in the cytoplasm, rapidly releasing siRNA to exert its gene silencing function. This not only improves the biosafety of the lipid nanoparticles but also enhances the delivery efficiency of siRNA. This provides a new strategy and option for solving the toxic side effects and delivery efficiency issues of lipid nanoparticles, meeting the urgent clinical need for highly efficient and low-toxicity nucleic acid drug formulations.

Disclosed herein are drug delivery implants configured to be implanted into the eye of a subject and serve as intraocular drug depots. The implants reside in an intraocular target site until activation, at which time the implants release the drug (or drugs) housed within the implant in a controlled release fashion. The drug delivery implant can include an outer shell, a stabilized travoprost formulation positioned within an inner chamber of the outer shell, and an elution rate-controlling membrane such as ethylene vinyl acetate copolymer membrane. The stabilized travoprost formulation can include travoprost and an effective amount of at least one antioxidant. The elution rate-controlling membrane can be in operable contact with the stabilized travoprost formulation and can deliver a therapeutically effective amount of the travoprost from the inner chamber to an ocular space including anterior and posterior chambers.

This application discloses the use of neuroprotective agent D1 (NPD1) in the preparation of drugs to relieve / treat chronic pruritus, relating to the field of biomedical technology. This invention provides NPD1 that can reverse spinal cord demyelination and relieve chronic pruritus. NPD1 can be used to relieve and / or treat chronic dermatitis pruritus, particularly showing excellent inhibitory effects against allergic contact dermatitis. The NPD1 can be developed into conventional lipid nanoparticles (LNPs) or other similar lipid nanoparticle drug formulations for drug delivery, possessing significant potential application value for relieving itching. The NPD1 developed in this invention can directly relieve pruritus abnormalities caused by dorsal horn demyelination of the mouse spinal cord, fundamentally inhibiting the occurrence of pruritus abnormalities in chronic dermatitis, solving the clinical problem of chronic pruritus that plagues patients with chronic dermatitis, and providing a new and effective solution for the clinical treatment of chronic dermatitis, especially pruritus in allergic contact dermatitis.

This invention discloses a preventive drug formulation for porcine reproductive and respiratory syndrome (PRRS) and its preparation method. The drug formulation uses tylosin tartrate as the active ingredient, loaded onto a blank cellulose carrier to obtain drug carrier nanoparticles, which are then coated with a blocking solution. The blocking solution is obtained by dispersing methacrylate-ethyl acrylate copolymer, triethyl citrate, and talc in deionized water. This invention utilizes the technical characteristics of synthesizing a spirocyclic phosphate diacyl chloride intermediate using pentaerythritol and phosphorus oxychloride, and reacting it with guanidine hydrochloride to construct a guanidine-functionalized crosslinking agent. This results in a guanidine-based intermediate with a rigid spirocyclic structure, providing stable crosslinking sites and spatial framework support for subsequent cellulose crosslinking, achieving the fundamental technical effect of constructing a three-dimensional network porous carrier framework.

This invention belongs to the field of traditional Chinese medicine composition technology, and discloses a composition for treating pulmonary fibrosis, its preparation method, and its application. The weight percentage of the composition is: ginseng 15-25%, Chamaejasminoides 40-60%, tangerine peel 15-30%, Buddha's hand or tangerine peel 12-15%; or ginseng saponin extract 5-15%, ginseng polysaccharide 5-10%, Chamaejasminoides polysaccharide 25-35%, tangerine peel water extract 20-25%, and Buddha's hand water extract with alcohol precipitation 15-25%. The preparation method of the composition includes S1, weighing the raw materials and decocting them with water; S2, filtering and concentrating the raw material solution, then adding alcohol and stirring, allowing it to precipitate overnight, filtering to remove the precipitate, and recovering the ethanol from the supernatant; then concentrating it into a concentrated solution for later use or drying it into a paste and pulverizing it into powder; S3, adding excipients to obtain an oral drug formulation. The composition is used in the preparation of drugs for the prevention and / or treatment of pulmonary fibrosis and / or idiopathic pulmonary fibrosis.

Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

Disclosed herein are drug delivery implants configured to be implanted into the eye of a subject and serve as intraocular drug depots. The implants reside in an intraocular target site until activation, at which time the implants release the drug (or drugs) housed within the implant in a controlled release fashion. The drug delivery implant can include an outer shell, a stabilized travoprost formulation positioned within an inner chamber of the outer shell, and an elution rate-controlling membrane such as ethylene vinyl acetate copolymer membrane. The stabilized travoprost formulation can include travoprost and an effective amount of at least one antioxidant. The elution rate-controlling membrane can be in operable contact with the stabilized travoprost formulation and can deliver a therapeutically effective amount of the travoprost from the inner chamber to an ocular space including anterior and posterior chambers.